Aurinia Pharmaceuticals (AUPH) Price & Analysis

Compare

2,110 Followers

AUPH Stock Chart & Stats

$14.53

$0.10(1.19%)

At close: Jan 08 4:00 PM EST

$14.53

$0.10(1.19%)

Day’s Range― - ―

52-Week Range$6.55 - $16.54

Previous CloseN/A

Volume460.34K

Average Volume (3M)951.73K

Market Cap

$1.90B

Enterprise Value$1.92B

Total Cash (Recent Filing)$351.81M

Total Debt (Recent Filing)$78.21M

Price to Earnings (P/E)25.9

Beta0.48

Next Earnings

Mar 04, 2026

EPS Estimate

0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.23

Shares Outstanding131,840,560

10 Day Avg. Volume956,441

30 Day Avg. Volume951,733

Financial Highlights & Ratios

PEG Ratio-2.08

Price to Book (P/B)3.40

Price to Sales (P/S)5.46

P/FCF Ratio29.13

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue7.23

Enterprise Value/Gross Profit8.14

Enterprise Value/Ebitda18.75

Forecast

1Y Price Target

$16.00

Price Target Upside10.12% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentAnalyst notes Aritinercept is advancing toward clinical studies for autoimmune indications with encouraging earlier data, offering potential long-term upside if trials validate efficacy.

GuidanceAnalyst highlights management raised total revenue guidance for a second time, signaling increased confidence in demand for Lupkynis and the company's revenue trajectory.

Product SalesAnalyst points to a 27% year-over-year increase in Lupkynis net sales, driven by high-volume rheumatologists and hospital channel, which supports sustained top-line momentum.

Bears Say

Aurinia Pharmaceuticals News

Aurinia Pharmaceuticals downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Aurinia Pharmaceuticals (AUPH) to Market Perform from Outperform with a price target of $16, up from...

2M ago

AUPH

Aurinia Pharmaceuticals downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Aurinia Pharmaceuticals (AUPH) to Market Perform from Outperform with a $16 price target Published first on...

2M ago

AUPH

Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies

Jefferies upgraded Aurinia Pharmaceuticals (AUPH) to Buy from Hold with a price target of $21, up from $10....

3M ago

AUPH

Aurinia Pharmaceuticals Reports Strong Q3 2025 Earnings

Aurinia Pharmaceuticals ( ($AUPH) ) has released its Q3 earnings. Here is a breakdown of the information Aurinia...

3M ago

AUPH

Aurinia Pharma’s Earnings Call Highlights Growth and Challenges

Aurinia Pharmaceuticals (($AUPH)) has held its Q3 earnings call. Read on for the main highlights of the call....

3M ago

AUPH

Aurinia downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded Aurinia Pharmaceuticals (AUPH) to Sector Perform from Outperform with a price target of $15, up...

3M ago

AUPH

Promising Sales and Market Potential of Lupkynis Drive Buy Rating for Aurinia Pharmaceuticals

Analyst Stacy Ku of TD Cowen maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of...

3M ago

AUPH

Aurinia Pharmaceuticals Boosts 2025 Sales Guidance Amid Strong Q3 Performance

Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals reported a significant increase in financial performance...

3M ago

AUPH

Aurinia Pharmaceuticals Reports Strong Q3 2025 Growth and Raises Sales Guidance

An update from Aurinia Pharmaceuticals ( ($AUPH) ) is now available. Aurinia Pharmaceuticals reported significant financial growth for...

3M ago

AUPH

Aurinia Pharmaceuticals reports Q3 EPS 23c, consensus 16c

Reports Q3 revenue $73.5M, consensus $67.7M. “LUPKYNIS sales experienced continued momentum following last year’s update to the American...

3M ago

AUPH

Aurinia Pharmaceuticals raises FY25 revenue view to $275M-$280M from $260M-$270M

FY25 consensus $270.48M. For 2025, Aurinia is increasing total revenue guidance from a range of $260 million to...

3M ago

AUPH

Midday Fly By: AWS in deal with OpenAI, Kimberly-Clark to buy Kenvue

The major averages were mixed near noon, with the S&P 500 and Nasdaq higher as investors start the...

3M ago

Aurinia Pharmaceuticals to Announce Q3 2025 Financial Results and Business Update

Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals announced it will report its financial results...

3M ago

AUPH

FDA official resigns, sued by Aurinia Pharmaceuticals, WSJ reports

An FDA official who recently resign is being sued by Aurinia Pharmaceuticals (AUPH) for allegedly soliciting a bribe...

3M ago

AUPH

AUPH FAQ

What was Aurinia Pharmaceuticals’s price range in the past 12 months?

Aurinia Pharmaceuticals lowest stock price was $6.55 and its highest was $16.54 in the past 12 months.

What is Aurinia Pharmaceuticals’s market cap?

Aurinia Pharmaceuticals’s market cap is $1.90B.

When is Aurinia Pharmaceuticals’s upcoming earnings report date?

Aurinia Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 21 days.

How were Aurinia Pharmaceuticals’s earnings last quarter?

Aurinia Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.07.

Is Aurinia Pharmaceuticals overvalued?

According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aurinia Pharmaceuticals pay dividends?

Aurinia Pharmaceuticals does not currently pay dividends.

What is Aurinia Pharmaceuticals’s EPS estimate?

Aurinia Pharmaceuticals’s EPS estimate is 0.22.

How many shares outstanding does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals has 131,840,560 shares outstanding.

What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?

Aurinia Pharmaceuticals reported an EPS of $0.23 in its last earnings report, beating expectations of $0.16. Following the earnings report the stock price went up 8.352%.

Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?

Currently, no hedge funds are holding shares in AUPH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Aurinia Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

20.65%

Trailing 12-Months

Asset Growth

-3.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Aurinia Pharmaceuticals (AUPH) Earnings & Revenues

Historic Earnings Reports

AUPH Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call showed strong sales growth and financial performance, particularly for LUPKYNIS, alongside promising clinical developments with aritinercept. However, regulatory and legal issues present potential challenges.View all AUPH earnings summaries

AUPH Revenue Breakdown

90.00% U.S.

10.00% Japan

AUPH Stock 12 Month Forecast

Average Price Target

$16.00

▲(10.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","17":"$17","8.75":"$8.75","11.5":"$11.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,8.75,11.5,14.25,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.22,15.280000000000001,15.34,15.4,15.46,15.52,15.58,15.64,15.700000000000001,15.76,15.82,15.88,15.94,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.22,15.280000000000001,15.34,15.4,15.46,15.52,15.58,15.64,15.700000000000001,15.76,15.82,15.88,15.94,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.22,15.280000000000001,15.34,15.4,15.46,15.52,15.58,15.64,15.700000000000001,15.76,15.82,15.88,15.94,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.95,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.17,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >